[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jennifer Keiser\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100612791","phase-2-efficacy-and-safety-of-a-single-dose-of-emodepside-compared-to-a-single-dose-of-albendazole-in-adolescents-and-adults-infected-with-trichuris-incognita-100612791",false,"NCT07258173","Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita","Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita: a Phase II, Randomized, Double Blind, Controlled Trial","EMOTI","Inclusion Criteria:\n\n* Aged 12 years and above.\n* Written informed consent signed by participant and, in the case of minors, parents\u002Fcaregivers.\n* Agree to comply with study procedures, including provision of two stool samples at the beginning (screening) and at follow-up assessment 14-21 days after treatment.\n* Having at least two slides of the quadruple Kato-Katz thick smears positive for Trichuris incognita and infection intensities of at least 48 eggs per gram (EPG).\n* Willing to be examined by a study physician prior to treatment.\n\nExclusion Criteria:\n\n* Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38 °C, severe anemia (Hb below 80g\u002Fl) upon initial clinical assessment etc.\n* History of severe acute or unmanaged severe chronic disease (i.e., condition is not as therapeutically controlled as necessary).\n* Positive malaria rapid diagnostic test (RDT) and temperature ≥ 38 °C.\n* Abnormal liver and renal function assessed by biochemical blood-based analyses.\n* Recent use of anthelmintic drugs (in the 4 weeks before treatment).\n* Known allergy to study medications and formulations (i.e. albendazole and emodepside).\n* Prescribed or taking medication with known contraindication to or interaction with study drugs.\n* Participating in other clinical trials during the study period.\n* Pregnancy or breastfeeding.","ALL","12 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this clinical trial is to compare the efficacy and safety of emodepside with the standard treatment, albendazole, in adolescents (12 years and older) and adults infected with Trichuris incognita.",[27],"Trichuris Infection",[29,30,31,32,33,34,35],"Trichuris incognita","emodepside","efficacy","safety","soil transmitted helminths","Trichuris","Côte d'Ivoire","NOT_YET_RECRUITING","2026-05-04",{"date":39,"type":40},"2026-05-08","ACTUAL",{"date":42,"type":21},"2026-05-15",{"date":44,"type":21},"2026-09-15",{"name":46,"class":47},"Jennifer Keiser","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100613148","phase-2-efficacy-and-safety-of-ascending-doses-of-arpraziquantel-in-children-infected-with-opisthorchis-viverrini-100613148","NCT07262814","Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini","Efficacy, Safety and Acceptability of Ascending Doses of Arpraziquantel for Opisthorchis Viverrini Infections in Children Aged 6-7 Years: A Single-blind Randomized Dose-ranging Trial","ADORA-VI","Inclusion Criteria:\n\n* Aged 6 to 7 years (i.e., 72 to 95 months).\n* Written informed consent signed by parents\u002Fcaregivers (signature or thumbprint).\n* Agree to comply with study procedures, including provision of two stool samples at baseline and at follow-up assessment 21-28 days after treatment, respectively.\n* Willing to be examined by a study physician prior to treatment.\n* At least two slides of the quadruple Kato-Katz thick smears positive for O. viverrini.\n\nExclusion Criteria:\n\n* Presence or signs of major systemic illness, e.g. severe anaemia (haemoglobin level of \\\u003C 80 g\u002FL according to WHO) upon initial clinical assessment.\n* Known or suspected infection with Taenia solium (cysticercosis).\n* Known or suspected acute schistosomiasis.\n* Abnormal liver and kidney function.\n* Use of anthelminthic drugs within 4 weeks before or during study period.\n* Known allergy to study medications (i.e. praziquantel or any of the excipients).\n* Being prescribed or taking concomitantly medication with known contraindication or drug interactions with the study medication.\n* Concurrent participation in other clinical trials.","6 Years","7 Years",{"count":59,"type":21},125,[24],"This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini. The primary objective is to determine the dose-response relationship in terms of cure rate. This study will involve children aged 6-7 years, since O. viverrini infections often occur in pre-school and school-aged children, and this group is largely left untreated in current public health programs.",[63],"Opisthorchis Viverrini","2026-03-17",{"date":66,"type":40},"2026-03-20",{"date":68,"type":21},"2026-04-15",{"date":70,"type":21},"2026-08",{"name":46,"class":47},1,""]